SCHEMBL6282073

SCHEMBL6282073

CC1CN1C(=O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPMT P51580 1/20 0.43
HSD11B1 P28845 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SLC6A7 Q99884 2/20 0.41
POLB P06746 1/20 0.40
GAA P10253 2/20 0.40
HTR3E A5X5Y0 1/20 0.40
GMNN O75496 1/20 0.40
HTR3B O95264 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
MTOR P42345 1/20 0.40
HTR3A P46098 1/20 0.40
PMP22 Q01453 1/20 0.40
HTR3D Q70Z44 1/20 0.40
HTR3C Q8WXA8 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3887377 0.82 L3MBTL1 (0.54) HTTL3MBTL1GAACYP2D6HSD17B10
SCHEMBL3888129 0.81 SLC6A7 (0.57) SLC6A7POLBGAAHSD17B10HPGD
SCHEMBL19070285 0.79 VNN1 (0.46) GAAHPGD
SCHEMBL3890994 0.78 ALDH1A1 (0.59) TPMTHTTL3MBTL1GAAHTR3E
SCHEMBL17098969 0.77 GAA (0.60) HTTL3MBTL1SLC6A7GAAHPGD
SCHEMBL133281 0.74 HTT (0.60) HTTL3MBTL1GAAHSD17B10HPGD
SCHEMBL1935843 0.74 HTT (0.60) HTTL3MBTL1GAAHSD17B10HPGD
SCHEMBL26925417 0.74 SLC6A7 (0.51) SLC6A7POLBGAAHSD17B10HPGD
SCHEMBL18908846 0.74 GRM5 (0.52) HSD11B1POLBCYP2D6HPGDALDH1A1
SCHEMBL6601480 0.73 TPMT (0.59) TPMTHTTL3MBTL1GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6962933-B1 Method for inhibiting p38 MAP kinase or TNF-α production using a 1,3-thiazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-11-08 US disclosed
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed
US-20040097555-A1 Concomitant drugs TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-20 US disclosed
EP-1402900-A1 MEDICINAL COMPOSITIONS Takeda Chemical Industries, Ltd. (JP) 2004-03-31 EP disclosed
EP-1354603-A1 CONCOMITANT DRUGS Takeda Chemical Industries, Ltd. (JP) 2003-10-22 EP disclosed
EP-1205478-A1 p38MAP KINASE INHIBITORS Takeda Chemical Industries, Ltd. (JP) 2002-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 TPMT 1968/4885HSD11B1 2409/4885HTT 4847/4885
US-20040097555-A1 Concomitant drugs TNF, CHUK, CNKSR1 TPMT 57/4885HSD11B1 1616/4885HTT 3987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.